Abstract
In this issue of Blood, Rothe et al introduce a new principle of targeted Hodgkin lymphoma (HL) immunotherapy in their report from a phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13.
Cite
CITATION STYLE
APA
Hutchings, M. (2015, June 25). Targeted immunotherapy in Hodgkin lymphoma. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2015-05-641712
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free